ArticleJCO oncology practice2020
Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Article in JCO oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review.Future oncology (London, England) · 2025Pooled it
- Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial.JCO oncology practice · 2023Trial
- Chrónos and Káiros in theragnostics: re-assessing time toxicity in final-line radiopharmaceutical treatments.European journal of nuclear medicine and molecular imaging · 2026Article
- An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer.The oncologist · 2026Article
- The experience of time toxicity in cancer patients: a meta-synthesis of qualitative research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Communication practices and experience of connection in telehealth serious illness conversations with rural cancer patients: a qualitative study.BMC palliative care · 2026Article
- Withstanding the test of time for patients in oncology clinical trials.The oncologist · 2026Article
- Planned time burden for patients participating in phase 2 cancer trials.The oncologist · 2026Article
- Article
- A novel patient-centered outcome in cancer care, days at home: a scoping review and guide for its future use.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Oncologist perspectives on the time toxicity of palliative systemic treatments for advanced cancer.JNCI cancer spectrum · 2026Article
- A patient journey map study on time toxicity among young and middle-aged patients with breast cancer.Frontiers in public health · 2026Article
- Time toxicity during palliative chemotherapy for advanced malignancies: a prospective study.BMJ supportive & palliative care · 2025Observational
- Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer.Journal of gastrointestinal cancer · 2025Article
- Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.Immunotherapy · 2025Article
- Opportunities for Home Cancer Care: The Final Frontier.NEJM catalyst innovations in care delivery · 2025Article
- Palliative semi-permanent abdominal drain for the management of refractory malignant ascites: a retrospective study in a comprehensive cancer center.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- A Text Message Intervention to Minimize the Time Burden of Cancer Care.NEJM catalyst innovations in care delivery · 2025Article
- Time toxicity in cancer treatment: oncologists' knowledge and practices across Pakistan.Ecancermedicalscience · 2025Article
- Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen.Frontiers in oncology · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeThe median overall survival (OS) for metastatic pancreatic ductal adenocarcinoma (mPDAC) is < 1 year. Factors that contribute to quality of life during treatment are critical to quantify. One factor-time spent obtaining clinical services-is understudied. We quantified total outpatient time among patients with mPDAC receiving palliative systemic chemotherapy.
methodsWe conducted a retrospective analysis using four patient-level time measures calculated from the medical record of patients with mPDAC receiving 5-fluorouracil infusion, leucovorin, oxaliplatin, and irinotecan; gemcitabine/nab-paclitaxel; or gemcitabine within the University of Pennsylvania Health System between January 1, 2011 and January 15, 2019. These included the total number of health care encounter days (any day with at least one visit) and total visit time. Total visit time represented the time spent receiving care (care time) plus time spent commuting and waiting for care (noncare time). We performed descriptive statistics on these outpatient time metrics and compared the number of encounter days to OS.
resultsA total of 362 patients were identified (median age, 65 years; 52% male; 78% white; 62% received gemcitabine plus nab-paclitaxel). Median OS was 230.5 days (7.6 months), with 79% of patients deceased at the end of follow-up. On average, patients had 22 health care encounter days, accounting for 10% of their total days survived. Median visit time was 4.6 hours, of which 2.5 hours was spent commuting or waiting for care.
conclusionOn average, patients receiving palliative chemotherapy for mPDAC spend 10% of survival time on outpatient health care. More than half of this time is spent commuting and waiting for care. These findings provide an important snapshot of the patient experience during ambulatory care, and efforts to enhance efficiency of care delivery may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.